- Home
- LFT vs CCCC Comparison
LFT vs CCCC Comparison
Compare LFT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- CCCC
- Stock Information
- Founded
- LFT 2012
- CCCC 2015
- Country
- LFT United States
- CCCC United States
- Employees
- LFT N/A
- CCCC N/A
- Industry
- LFT Real Estate Investment Trusts
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- LFT Real Estate
- CCCC Health Care
- Exchange
- LFT Nasdaq
- CCCC Nasdaq
- Market Cap
- LFT 125.6M
- CCCC 104.4M
- IPO Year
- LFT N/A
- CCCC 2020
- Fundamental
- Price
- LFT $2.20
- CCCC $1.43
- Analyst Decision
- LFT Hold
- CCCC Buy
- Analyst Count
- LFT 2
- CCCC 3
- Target Price
- LFT N/A
- CCCC $12.00
- AVG Volume (30 Days)
- LFT 376.6K
- CCCC 1.3M
- Earning Date
- LFT 08-11-2025
- CCCC 07-31-2025
- Dividend Yield
- LFT 14.68%
- CCCC N/A
- EPS Growth
- LFT N/A
- CCCC N/A
- EPS
- LFT 0.20
- CCCC N/A
- Revenue
- LFT $27,066,283.00
- CCCC $39,783,000.00
- Revenue This Year
- LFT $152.58
- CCCC N/A
- Revenue Next Year
- LFT N/A
- CCCC N/A
- P/E Ratio
- LFT $10.95
- CCCC N/A
- Revenue Growth
- LFT N/A
- CCCC 98.56
- 52 Week Low
- LFT $2.16
- CCCC $1.09
- 52 Week High
- LFT $2.84
- CCCC $7.66
- Technical
- Relative Strength Index (RSI)
- LFT 30.32
- CCCC 50.43
- Support Level
- LFT $2.29
- CCCC $1.36
- Resistance Level
- LFT $2.63
- CCCC $1.63
- Average True Range (ATR)
- LFT 0.08
- CCCC 0.14
- MACD
- LFT -0.03
- CCCC -0.00
- Stochastic Oscillator
- LFT 8.14
- CCCC 38.10
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.